171 related articles for article (PubMed ID: 26512963)
1. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.
Zhou J; Ning Z; Wang B; Yun EJ; Zhang T; Pong RC; Fazli L; Gleave M; Zeng J; Fan J; Wang X; Li L; Hsieh JT; He D; Wu K
Cell Death Dis; 2015 Oct; 6(10):e1955. PubMed ID: 26512963
[TBL] [Abstract][Full Text] [Related]
2. The role of DAB2IP in androgen receptor activation during prostate cancer progression.
Wu K; Liu J; Tseng SF; Gore C; Ning Z; Sharifi N; Fazli L; Gleave M; Kapur P; Xiao G; Sun X; Oz OK; Min W; Alexandrakis G; Yang CR; Hsieh CL; Wu HC; He D; Xie D; Hsieh JT
Oncogene; 2014 Apr; 33(15):1954-63. PubMed ID: 23604126
[TBL] [Abstract][Full Text] [Related]
3. DAB2IP regulates intratumoral testosterone synthesis and CRPC tumor growth by ETS1/AKR1C3 signaling.
Gu Y; Wu S; Chong Y; Guan B; Li L; He D; Wang X; Wang B; Wu K
Cell Signal; 2022 Jul; 95():110336. PubMed ID: 35452821
[TBL] [Abstract][Full Text] [Related]
4. Decreased DAB2IP gene expression, which could be induced by fractionated irradiation, is associated with resistance to γ‑rays and α‑particles in prostate cancer cells.
Yang C; He H; Zhang T; Chen Y; Kong Z
Mol Med Rep; 2016 Jul; 14(1):567-73. PubMed ID: 27177018
[TBL] [Abstract][Full Text] [Related]
5. DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor.
Yu L; Tumati V; Tseng SF; Hsu FM; Kim DN; Hong D; Hsieh JT; Jacobs C; Kapur P; Saha D
Neoplasia; 2012 Dec; 14(12):1203-12. PubMed ID: 23308052
[TBL] [Abstract][Full Text] [Related]
6. PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.
Zhang D; He D; Xue Y; Wang R; Wu K; Xie H; Zeng J; Wang X; Zhau HE; Chung LW; Chang LS; Li L
Cancer Res; 2011 Mar; 71(6):2193-202. PubMed ID: 21385902
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression.
Huang S; Liu Q; Liao Q; Wu Q; Sun B; Yang Z; Hu X; Tan M; Li L
Cancer Sci; 2018 Mar; 109(3):678-687. PubMed ID: 29288516
[TBL] [Abstract][Full Text] [Related]
8. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.
Xie D; Gore C; Zhou J; Pong RC; Zhang H; Yu L; Vessella RL; Min W; Hsieh JT
Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19878-83. PubMed ID: 19903888
[TBL] [Abstract][Full Text] [Related]
9. Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.
Kong Z; Raghavan P; Xie D; Boike T; Burma S; Chen D; Chakraborty A; Hsieh JT; Saha D
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1210-8. PubMed ID: 20970033
[TBL] [Abstract][Full Text] [Related]
10. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.
Xie D; Gore C; Liu J; Pong RC; Mason R; Hao G; Long M; Kabbani W; Yu L; Zhang H; Chen H; Sun X; Boothman DA; Min W; Hsieh JT
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2485-90. PubMed ID: 20080667
[TBL] [Abstract][Full Text] [Related]
11. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling.
Wu K; Wang B; Chen Y; Zhou J; Huang J; Hui K; Zeng J; Zhu J; Zhang K; Li L; Guo P; Wang X; Hsieh JT; He D; Fan J
Cell Signal; 2015 Dec; 27(12):2515-23. PubMed ID: 26410305
[TBL] [Abstract][Full Text] [Related]
12. The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth.
Tsai YS; Lai CL; Lai CH; Chang KH; Wu K; Tseng SF; Fazli L; Gleave M; Xiao G; Gandee L; Sharifi N; Moro L; Tzai TS; Hsieh JT
Oncotarget; 2014 Aug; 5(15):6425-36. PubMed ID: 25115390
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation.
Kong Z; Xie D; Boike T; Raghavan P; Burma S; Chen DJ; Habib AA; Chakraborty A; Hsieh JT; Saha D
Cancer Res; 2010 Apr; 70(7):2829-39. PubMed ID: 20332235
[TBL] [Abstract][Full Text] [Related]
14. Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity.
Jeon YJ; Jung SN; Yun J; Lee CW; Choi J; Lee YJ; Han DC; Kwon BM
Cancer Sci; 2015 Apr; 106(4):413-20. PubMed ID: 25611086
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
16. DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein.
Wang B; Huang J; Zhou J; Hui K; Xu S; Fan J; Li L; Wang X; Hsieh JT; He D; Wu K
Cell Signal; 2016 Nov; 28(11):1623-30. PubMed ID: 27476001
[TBL] [Abstract][Full Text] [Related]
17. Cancer-driven IgG promotes the development of prostate cancer though the SOX2-CIgG pathway.
Qin C; Sheng Z; Huang X; Tang J; Liu Y; Xu T; Qiu X
Prostate; 2020 Sep; 80(13):1134-1144. PubMed ID: 32628304
[TBL] [Abstract][Full Text] [Related]
18. Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.
Marampon F; Gravina G; Ju X; Vetuschi A; Sferra R; Casimiro M; Pompili S; Festuccia C; Colapietro A; Gaudio E; Di Cesare E; Tombolini V; Pestell RG
Oncotarget; 2016 Feb; 7(5):5383-400. PubMed ID: 26689991
[TBL] [Abstract][Full Text] [Related]
19. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells.
Duan Y; Yin X; Lai X; Liu C; Nie W; Li D; Xie Z; Li Z; Meng F
Technol Cancer Res Treat; 2020; 19():1533033819895494. PubMed ID: 32336215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
